Schedule 13G ownership disclosure

Rapport Therapeutics Inc

Common Stock, $0.001 par value · CUSIP: 75383L102

Event date: 2025-09-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • JOHNSON & JOHNSON

    Shares: 1,784,517.00 · Class: 4.9%

  • Johnson & Johnson Innovation - JJDC, Inc.

    Shares: 1,784,517.00 · Class: 4.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000904454-25-000502
Form type
SCHEDULE 13G/A
Filer
JOHNSON & JOHNSON
CIK
CIK 200406
Filed
Oct 22, 2025
Reporting period
Sep 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub